baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UC WAR. CALL 06/24 SNW/ DE000HD4YZS8 /

2024-05-22 3:46:53 PM	Chg.-0.0100	Bid4:15:33 PM	Ask4:15:33 PM	Underlying	Strike price	Expiration date	Option type
0.1000EUR	-9.09%	0.1100 Bid Size: 175,000	0.1200 Ask Size: 175,000	SANOFI SA INHABER ...	92.00 -	2024-06-19	Call

GlobeNewswire 05-21 Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration

GlobeNewswire 05-20 Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...

GlobeNewswire 05-20 Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...

GlobeNewswire 05-20 Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meet...

GlobeNewswire 05-13 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...

GlobeNewswire 05-13 Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...

TeleTrader 05-13 Europe mixed at open as CPI prints loom

GlobeNewswire 05-13 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...

TeleTrader 05-10 Novavax skyrockets 213.5% in premarket, highest in 16 months

TeleTrader 05-10 Novavax soars 39.6% in premarket after Sanofi license deal

GlobeNewswire 05-10 Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVI...

GlobeNewswire 05-09 Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab

TeleTrader 05-09 Europe opens mixed with BoE in focus

GlobeNewswire 05-08 IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire 05-07 Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

GlobeNewswire 05-02 Regeneron Reports First Quarter 2024 Financial and Operating Results

GlobeNewswire 05-02 Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant R...

GlobeNewswire 04-30 Press Release: Annual General Meeting of April 30, 2024

TeleTrader 04-25 Europe opens mostly down after corporate earnings

TeleTrader 04-25 Europe down in premarket as financial results pour in

TeleTrader 04-25 Sanofi books net sales of €10.5B in Q1, up 2.4%

GlobeNewswire 04-25 Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance

GlobeNewswire 04-23 Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia

GlobeNewswire 04-17 IGM Biosciences Announces Refocusing of Sanofi Collaboration

GlobeNewswire 04-17 Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in ...

UC WAR. CALL 06/24 SNW/ DE000HD4YZS8 /

If you wish to receive reply to your feedback, please provide your email address.